Kauliv

Teriparatide, the active ingredient in Kauliv, is a parathyroid hormone analog presented as a subcutaneous injection for subcutaneous use. It treats postmenopausal osteoporosis, male osteoporosis at high risk of fracture, and glucocorticoid‑induced osteoporosis.

GNH USA supplies Kauliv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from regulatory support, transparent pricing, and timely delivery to meet clinical demand across multiple regions.

Teriparatide is used as an anabolic therapy for bone loss conditions, targeting the skeletal remodeling pathway. - Postmenopausal osteoporosis: increases bone mineral density and reduces vertebral and non‑vertebral fracture risk in postmenopausal women. - Male osteoporosis at high risk of fracture: promotes bone formation to improve skeletal strength in men with severe osteoporosis. - Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss by stimulating osteoblast activity.

Teriparatide may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate sensation of stomach upset, usually transient. - Headache: occasional throbbing or pressure headache that resolves without treatment. - Dizziness: brief episodes of light‑headedness, particularly after injection. - Injection site reactions: redness, swelling, itching or mild pain at the subcutaneous site. - Hypercalcemia: slight increase in blood calcium that is often asymptomatic.

Serious or Rare Side Effects: - Osteosarcoma: extremely rare malignant bone tumor observed in long‑term animal studies, with limited human cases. - Severe hypercalcemia: marked elevation of calcium that can cause cardiac arrhythmia, renal impairment, or neurological symptoms. - Hypersensitivity reactions: anaphylactic response or severe skin rash requiring immediate medical attention. - Hypotension: sudden drop in blood pressure following injection, potentially leading to fainting. - Acute pancreatitis: rare inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

When prescribing Teriparatide, clinicians should consider several precautionary measures to ensure safe use. - Assess baseline calcium: verify normal serum calcium and vitamin D levels before initiating therapy. - Monitor bone turnover: periodic measurement of bone markers and densitometry to evaluate response. - Evaluate fracture risk: use only in patients with high fracture risk who have failed or cannot tolerate anti‑resorptive agents. - Limit duration: limit treatment to the approved maximum period (typically 2 years) to reduce rare malignancy risk. - Contraindications: avoid use in patients with prior radiation therapy involving the skeleton or known bone metastases. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the prefilled syringe.

Teriparatide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Hypercalcemic agents: concurrent use of calcium supplements or vitamin D excess may cause severe hypercalcemia. - Bisphosphonates: simultaneous administration can blunt the anabolic effect of Teriparatide.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce bone‑building response, requiring close monitoring of bone density. - Loop diuretics: increase calcium excretion and may alter serum calcium balance. - Anticonvulsants (e.g., phenytoin): induce hepatic enzymes that could affect calcium metabolism.